EPO

Detailed overview

Erythropoietin (EPO) is a 165-amino-acid glycoprotein cytokine (~30 kDa), endogenously produced by the kidney's peritubular interstitial cells (~90%) and to a small extent by the liver (~10%). The exogenous recombinant EPO (rhEPO) received FDA approval in 1989 from Amgen as Epogen (epoetin-alfa) for the treatment of chronic kidney disease (CKD) anemia – it was the first true recombinant therapeutic peptide blockbuster. Mechanism: EPO binds the EPO receptor (EPO-R) on the surface of erythroid progenitor cells (bone marrow BFU-E + CFU-E) → JAK2/STAT5 signaling cascade activation → erythroid survival + proliferation + differentiation → increase in RBC mass + hematocrit + oxygen-carrying capacity. Clinical Rx context (primary, ~75% of usage): CKD anemia (dialysis + pre-dialysis), chemotherapy-induced anemia (Procrit), HIV/AZT anemia, anemia of prematurity. Target Hb 10-12 g/dL – KDIGO 2024 cautions against Hb >12-13 g/dL targeting (TREAT, CHOIR, CREATE trial data: higher-target → cardiovascular events + stroke risk). Endurance-doping context (secondary, NOT endorsed): micro-dose protocols of 100-300 IU/kg/week documented since the 1990s (Lance Armstrong era), WADA-strictly-banned under S2.1 Erythropoietin-mimetic agents YEAR-ROUND (in + out-of-competition). Detection: serum/urine isoform analysis (IEF + SDS-PAGE) + biological passport hematocrit tracking. Sources: epoetin-alfa (Epogen Amgen, Procrit Janssen – same molecule), darbepoetin-alfa (Aranesp Amgen – hyperglycosylated, longer t1/2), methoxy-PEG-epoetin-beta (Mircera Roche – PEGylated, monthly dosing). MANDATORY bloodwork: Hb, Hct, ferritin, transferrin saturation, reticulocyte count, blood pressure (hypertension risk significant).